4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Validation of Cardiac Magnetic Resonance Sequences in Patients With Single Ventricles

Validation of Cardiac Magnetic Resonance Sequences in Patients With Single Ventricles

Study Description
Brief Summary:

Single ventricle defects make up the severe end of the congenital heart disease spectrum. The Fontan operation leads to a complete redirection of systemic venous blood outside of the heart and directly into the lungs. Patients with single ventricles suffer from multiple complications. Their survival has improved over the past decades, but is still severely compromised compared to the general population.

Their evaluation includes echocardiography and functional status by history and/or exercise testing. In longer intervals or if echocardiography does not allow visualization of all cardiovascular structures, cardiac magnetic resonance (CMR) is employed. Many patients also undergo more invasive cardiac catheterization.

In single ventricle patients, cardiac imaging has to address the questions of the patency of the Fontan pathways, i.e. all systemic veins, the Fontan conduit, and the pulmonary arteries, and of the function of the single ventricle (including myocardial function and valve function).

By using conventional imaging methods in Fontan patients, Ghelani et al. identified a CMR-based ventricular end-diastolic volume of > 125 ml/m2 and an echocardiographic global circumferential strain (GCS) value of higher than -17% to be strong predictors for a combined adverse outcome of death or heart transplantation. While interobserver reproducibility of single ventricle ejection fraction is similarly high by echocardiography, CMR is better in reliably measuring ventricular mass and diastolic volume and can provide additional information by MR feature tracking (strain), T1 mapping, and 4D flow measurements. Several substances that can be measured in the peripheral blood are being increasingly investigated as biomarkers of heart failure.

In conclusion, several advanced CMR sequences and new biomarkers have a potential role in the assessment and risk stratification of single ventricle patients. Every single published study has elucidated a particular use and aspect of these parameters, but broader correlations and prognostic values are still unclear.

The investigators hypothesize that myocardial strain (by feature tracking), myocardial fibrosis (by T1 mapping), and intracardiac flow disturbances (by 4D flow) along with biomarkers are diagnostic for single ventricle dysfunction and correlate with known prognostic factors.

This is a single center, prospective, observational cohort study. There will be no randomisation or blinding. Study setting: outpatients, cardiology clinic and radiology department, academic hospital. Every patient will be examined twice with a one-year interval (MR will only be repeated if clinically indicated).


Condition or disease Intervention/treatment
Single-ventricle Diagnostic Test: Cardiac Magnetic Resonance Imaging Diagnostic Test: Blood draw for hematocrit and heart failure biomarkers Diagnostic Test: Cardiopulmonary exercise test Diagnostic Test: Exhalomics Diagnostic Test: Quality of life questionnaire

Study Design
Layout table for study information
Study Type : Observational
Estimated Enrollment : 63 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation of Cardiac Magnetic Resonance Sequences in Patients With Single Ventricles
Estimated Study Start Date : September 1, 2019
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : August 31, 2023
Arms and Interventions
Group/Cohort Intervention/treatment
Single ventricle
Patients with single ventricle lesions
Diagnostic Test: Cardiac Magnetic Resonance Imaging
Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia

Diagnostic Test: Blood draw for hematocrit and heart failure biomarkers
Approximately 10 ml of blood will be drawn before administration of contrast medium.

Diagnostic Test: Cardiopulmonary exercise test
In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography

Diagnostic Test: Exhalomics
Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)

Diagnostic Test: Quality of life questionnaire
Questionnaire to be filled out by the Patient regarding quality of life perception

Outcome Measures
Primary Outcome Measures :
  1. Strain correlation with ventricular volume [ Time Frame: 1 year ]
    Strain correlation with ventricular volume measured by magnetic resonance imaging

  2. Strain correlation with clinical parameters [ Time Frame: 1 year ]
    Strain correlation with clinical parameters such as presence of arrhythmias on Holter-EKG, maximal oxygen consumption on cardio-pulmonary exercise testing (ml/(kg*min))


Secondary Outcome Measures :
  1. T1 values compared to previously established normal cohort [ Time Frame: 1 year ]
    T1 values compared to previously established normal cohort

  2. Blood and exhaled biomarkers of heart failure correlation with T1 mapping [ Time Frame: 1 year ]
    Blood and exhaled biomarkers of heart failure correlation with T1 mapping

  3. Intraventricular blood flow correlation with cardiac function [ Time Frame: 1 year ]
    Intraventricular blood flow correlation with cardiac ejection fraction measured by magnetic resonance imaging


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with single ventricle physiology
Criteria

Inclusion Criteria:

  • Patients of any age with functionally single ventricle (patients under age 8 who need anesthesia for CMR will not be actively recruited. They may be approached to participate only if the anesthesia and CMR examination have been planned independently for clinical purposes)
  • Written informed consent

Exclusion Criteria:

  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, inability to give assent or consent, etc. of the participant and/or his/her parents or legal caregivers
  • MR-incompatible implanted or accidentally incorporated metal device or claustrophobia that prohibits use of magnetic resonance imaging (patient and guardians fill out a questionnaire).
  • Pregnancy
  • Participation in another study is not an exclusion criterion, e.g. in a therapeutic trial.
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Barbara EU Burkhardt, MD +41442667111 barbara.burkhardt@kispi.uzh.ch
Contact: Silvia Hilfiker +41442663339 silvia.hilfiker@kispi.uzh.ch

Locations
Layout table for location information
Switzerland
University Children's Hospital Zürich, Switzerland
Zürich, ZH, Switzerland, 8032
Sponsors and Collaborators
Barbara Burkhardt
Investigators
Layout table for investigator information
Principal Investigator: Barbara EU Burkhardt, MD University of Zurich Children's Hospital
Tracking Information
First Submitted Date July 8, 2019
First Posted Date July 12, 2019
Last Update Posted Date July 12, 2019
Estimated Study Start Date September 1, 2019
Estimated Primary Completion Date August 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 11, 2019)
  • Strain correlation with ventricular volume [ Time Frame: 1 year ]
    Strain correlation with ventricular volume measured by magnetic resonance imaging
  • Strain correlation with clinical parameters [ Time Frame: 1 year ]
    Strain correlation with clinical parameters such as presence of arrhythmias on Holter-EKG, maximal oxygen consumption on cardio-pulmonary exercise testing (ml/(kg*min))
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: July 11, 2019)
  • T1 values compared to previously established normal cohort [ Time Frame: 1 year ]
    T1 values compared to previously established normal cohort
  • Blood and exhaled biomarkers of heart failure correlation with T1 mapping [ Time Frame: 1 year ]
    Blood and exhaled biomarkers of heart failure correlation with T1 mapping
  • Intraventricular blood flow correlation with cardiac function [ Time Frame: 1 year ]
    Intraventricular blood flow correlation with cardiac ejection fraction measured by magnetic resonance imaging
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Validation of Cardiac Magnetic Resonance Sequences in Patients With Single Ventricles
Official Title Validation of Cardiac Magnetic Resonance Sequences in Patients With Single Ventricles
Brief Summary

Single ventricle defects make up the severe end of the congenital heart disease spectrum. The Fontan operation leads to a complete redirection of systemic venous blood outside of the heart and directly into the lungs. Patients with single ventricles suffer from multiple complications. Their survival has improved over the past decades, but is still severely compromised compared to the general population.

Their evaluation includes echocardiography and functional status by history and/or exercise testing. In longer intervals or if echocardiography does not allow visualization of all cardiovascular structures, cardiac magnetic resonance (CMR) is employed. Many patients also undergo more invasive cardiac catheterization.

In single ventricle patients, cardiac imaging has to address the questions of the patency of the Fontan pathways, i.e. all systemic veins, the Fontan conduit, and the pulmonary arteries, and of the function of the single ventricle (including myocardial function and valve function).

By using conventional imaging methods in Fontan patients, Ghelani et al. identified a CMR-based ventricular end-diastolic volume of > 125 ml/m2 and an echocardiographic global circumferential strain (GCS) value of higher than -17% to be strong predictors for a combined adverse outcome of death or heart transplantation. While interobserver reproducibility of single ventricle ejection fraction is similarly high by echocardiography, CMR is better in reliably measuring ventricular mass and diastolic volume and can provide additional information by MR feature tracking (strain), T1 mapping, and 4D flow measurements. Several substances that can be measured in the peripheral blood are being increasingly investigated as biomarkers of heart failure.

In conclusion, several advanced CMR sequences and new biomarkers have a potential role in the assessment and risk stratification of single ventricle patients. Every single published study has elucidated a particular use and aspect of these parameters, but broader correlations and prognostic values are still unclear.

The investigators hypothesize that myocardial strain (by feature tracking), myocardial fibrosis (by T1 mapping), and intracardiac flow disturbances (by 4D flow) along with biomarkers are diagnostic for single ventricle dysfunction and correlate with known prognostic factors.

This is a single center, prospective, observational cohort study. There will be no randomisation or blinding. Study setting: outpatients, cardiology clinic and radiology department, academic hospital. Every patient will be examined twice with a one-year interval (MR will only be repeated if clinically indicated).

Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with single ventricle physiology
Condition Single-ventricle
Intervention
  • Diagnostic Test: Cardiac Magnetic Resonance Imaging
    Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
  • Diagnostic Test: Blood draw for hematocrit and heart failure biomarkers
    Approximately 10 ml of blood will be drawn before administration of contrast medium.
  • Diagnostic Test: Cardiopulmonary exercise test
    In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
  • Diagnostic Test: Exhalomics
    Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
  • Diagnostic Test: Quality of life questionnaire
    Questionnaire to be filled out by the Patient regarding quality of life perception
Study Groups/Cohorts Single ventricle
Patients with single ventricle lesions
Interventions:
  • Diagnostic Test: Cardiac Magnetic Resonance Imaging
  • Diagnostic Test: Blood draw for hematocrit and heart failure biomarkers
  • Diagnostic Test: Cardiopulmonary exercise test
  • Diagnostic Test: Exhalomics
  • Diagnostic Test: Quality of life questionnaire
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: July 11, 2019)
63
Original Estimated Enrollment Same as current
Estimated Study Completion Date August 31, 2023
Estimated Primary Completion Date August 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients of any age with functionally single ventricle (patients under age 8 who need anesthesia for CMR will not be actively recruited. They may be approached to participate only if the anesthesia and CMR examination have been planned independently for clinical purposes)
  • Written informed consent

Exclusion Criteria:

  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, inability to give assent or consent, etc. of the participant and/or his/her parents or legal caregivers
  • MR-incompatible implanted or accidentally incorporated metal device or claustrophobia that prohibits use of magnetic resonance imaging (patient and guardians fill out a questionnaire).
  • Pregnancy
  • Participation in another study is not an exclusion criterion, e.g. in a therapeutic trial.
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Barbara EU Burkhardt, MD +41442667111 barbara.burkhardt@kispi.uzh.ch
Contact: Silvia Hilfiker +41442663339 silvia.hilfiker@kispi.uzh.ch
Listed Location Countries Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number NCT04017494
Other Study ID Numbers SV-CMR
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Barbara Burkhardt, University Children's Hospital, Zurich
Study Sponsor Barbara Burkhardt
Collaborators Not Provided
Investigators
Principal Investigator: Barbara EU Burkhardt, MD University of Zurich Children's Hospital
PRS Account University Children's Hospital, Zurich
Verification Date July 2019